Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials
Publication date
2020-07
Authors
Belkouz, A
Wilmink, J W
Mohammad, Nadia Haj
Hagendoorn, Jeroen
de Vos-Geelen, J
Dejong, C H C
Homs, M Y V
Groot Koerkamp, B
van Gulik, T M
Van Oijen, Martijn
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
cc_by
Abstract
Patients with biliary tract cancer (BTC) have a high recurrence rate after complete surgical resection. To reduce the risk of recurrence and to improve survival, several chemotherapeutic agents that have shown to be active in locally advanced and metastatic BTC have been investigated in the adjuvant setting in prospective clinical trials. Based on the results of the BILCAP phase III trial, capecitabine was adapted as the standard of care by the ASCO clinical practice guideline. Ongoing randomized controlled trials mainly compare capecitabine with gemcitabine-based chemotherapy or chemoradiotherapy. This review provides an update of adjuvant therapy in BTC based on published data of phase II and III trials and ongoing randomized controlled trials (RCTs).
Keywords
Adjuvant therapy, Biliary tract cancer, Chemoradiotherapy, Chemotherapy, Cholangiocarcinoma, Neoadjuvant therapy, Hematology, Oncology, Review, Journal Article
Citation
Belkouz, A, Wilmink, J W, Haj Mohammad, N, Hagendoorn, J, de Vos-Geelen, J, Dejong, C H C, Homs, M Y V, Groot Koerkamp, B, van Gulik, T M, van Oijen, M G H, Punt, C J A & Klümpen, H 2020, 'Advances in adjuvant therapy of biliary tract cancer : an overview of current clinical evidence based on phase II and III trials', Critical Reviews in Oncology/Hematology, vol. 151, 102975. https://doi.org/10.1016/j.critrevonc.2020.102975